北京商报讯12月15日，心脉医疗发布公告称，公司董事长Jonathan Chen、董事霍庆福均因个人原因，申 请辞去各自担任的公司董事长、董事及董事会专门委员会相关职务，辞职后不再担任公司任何职务。 心脉医疗于12月15日召开董事会会议，同意将公司董事会人数由8名增加至9名，并同意提名孙洪斌、梁 敏、刘旭东为公司第三届董事会非独立董事候选人，同意选举孙洪斌为公司第三届董事会董事长，并以 2025年第二次临时股东会审议通过其为公司董事为生效前提，任期自其上任公司董事之日起至第三届董 事会任期届满之日止。 （文章来源：北京商报） ...

证券代码：688016 证券简称：心脉医疗 公告编号：2025-049 上海微创心脉医疗科技（集团）股份有限公司 关于非独立董事辞任及补选非独立董事、选举董事长 暨调整专门委员会成员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | | | | | | | 是否继 | 是否 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 存在 | | | | | | 原定任 | 离 | 续在上 | 未履 | | | | | | | 任 | 市公司 | | | 姓名 | 离任职务 | 离任时间 | | 期到期 | | | 行完 | | | | | | 日 | 原 | 及其控 | 毕的 | | | | | | | 因 | 股子公 | | | | | | | | | 司任职 | 公开 | | | | | | | | | 承诺 | | | 第三届董事会董事 | | | | 个 | | | | | 长、董事会战略与发 | 年 | | 2027 ...

证券代码：688016 证券简称：心脉医疗 公告编号：2025-050 （一） 股东会类型和届次 2025年第二次临时股东会 召开日期时间：2025 年 12 月 31 日 13 点 00 分 召开地点：上海市浦东新区康新公路 3399 弄 1 号楼 1 层公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 31 日 至2025 年 12 月 31 日 上海微创心脉医疗科技（集团）股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 股东会召开日期：2025年12月31日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （ ...

格隆汇12月15日丨心脉医疗(688016.SH)公布，公司董事长 Jonathan Chen 先生因个人原因申请辞去公司 董事长及董事会专门委员会的相关职务，辞职后将不再担任公司任何职务。 公司董事霍庆福先生因个人原因申请辞去公司董事及董事会专门委员会的相关职务，辞职后将不再担任 公司任何职务。 ...

Group 1 - The core viewpoint of the news is that Xinmai Medical (688016) has shown mixed financial performance in the third quarter of 2025, with a notable increase in revenue but a decline in net profit [2] - As of December 10, 2025, Xinmai Medical's stock closed at 91.62 yuan, with a slight increase of 0.22% and a trading volume of 8110 lots, amounting to a total transaction value of 73.91 million yuan [1] - The company reported a main revenue of 1.015 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 4.66%, while the net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2] Group 2 - In the third quarter of 2025, Xinmai Medical achieved a single-quarter revenue of 300 million yuan, which is a significant year-on-year increase of 64.68%, but the net profit attributable to shareholders fell by 23.63% to 114 million yuan [2] - The company has a debt ratio of 15.85% and reported an investment income of 11.6 million yuan, with financial expenses recorded at -7.86 million yuan and a gross profit margin of 70.4% [2] - Over the past 90 days, 9 institutions have provided ratings for the stock, with 7 buy ratings and 2 hold ratings, and the average target price set by institutions is 136.03 yuan [2]

Core Viewpoint - The stock of Xinmai Medical (688016) has shown a slight decline, with recent trading data indicating mixed capital flows among different investor categories, highlighting potential volatility in investor sentiment [1][2]. Group 1: Stock Performance - As of December 8, 2025, Xinmai Medical closed at 93.1 yuan, down 0.09% with a turnover rate of 0.72% and a trading volume of 8,897 lots, amounting to a total transaction value of 83.06 million yuan [1]. - Over the past five days, the stock has experienced fluctuations, with a notable increase of 1.28% on December 5, followed by a decline on subsequent days [2]. Group 2: Capital Flows - On December 8, 2025, the net inflow of main funds was 3.19 million yuan, accounting for 3.84% of the total transaction value, while retail investors saw a net outflow of 6.99 million yuan, representing 8.41% of the total [1][2]. - The recent five-day capital flow data indicates a trend of net outflows from retail investors, contrasting with net inflows from institutional and speculative funds on certain days [2]. Group 3: Financial Metrics and Industry Comparison - Xinmai Medical's total market capitalization is 11.476 billion yuan, with a net asset value of 3.982 billion yuan and a net profit of 429 million yuan, ranking 16th in the medical device industry [3]. - The company reported a gross margin of 70.4% and a net margin of 41.69%, significantly outperforming industry averages, with a price-to-earnings ratio of 20.06 compared to the industry average of 65.06 [3]. - For the first three quarters of 2025, Xinmai Medical's main revenue was 1.015 billion yuan, a year-on-year increase of 4.66%, while the net profit decreased by 22.46% [3]. Group 4: Analyst Ratings - In the last 90 days, nine institutions have provided ratings for Xinmai Medical, with seven recommending a buy and two suggesting an increase in holdings, indicating a generally positive outlook [4]. - The average target price set by institutions over the past 90 days is 136.03 yuan, suggesting potential upside from the current trading price [4].

Core Viewpoint - The pharmaceutical and biotechnology market currently lacks a clear main theme, but the release of the first "Medical Insurance + Commercial Insurance Dual Directory" by the National Healthcare Security Administration on December 7 may boost investment enthusiasm for innovative drugs [1] Market Performance - Last week, the pharmaceutical and biotechnology sector had a return of -0.74%, underperforming the CSI 300 by 2.02%, ranking 21st among 31 primary sub-industry indices [2] - The pharmaceutical commercial sub-sector had the highest weekly return at 5.19%, outperforming the CSI 300 by 3.91%, while the medical services sub-sector ranked sixth with a return of -1.37%, underperforming the CSI 300 by 2.65% [2] Innovative Drugs - Companies recommended for investment in innovative drugs include: - Innovent Biologics - 3SBio - Hengrui Medicine - Kelun-Biotech - Baillie Gifford - Rongchang Biologics - Yimeng Biologics - Huyou Pharmaceutical - King’s Ray Biotech - Valiant Biotech - Lee's Pharmaceutical [2] CXO and Life Sciences Upstream Industry Chain - Recommended global CXO leaders include: - WuXi AppTec - WuXi Biologics - WuXi AppTec's subsidiary - Kanglong Chemical - Kailai Ying [3] - Recommended domestic clinical CRO leaders include: - Tigermed - Proprius - Nossg - Sunshine Nuohe [3] - Recommended resource-type CXOs include: - Zhaoyan New Drug - Yinos - Medicy - Baiaosaitu - Yaokang Biotech [3] - Recommended companies in the life sciences upstream industry chain include: - Baipusais - Haoyuan Pharmaceutical - Bid Pharmaceutical - Nami Technology - Aopumai - Haier Biomedical - Aladdin - Titan Technology [3] Companies with Improved Operations and High Dividends - Companies recommended for attention include: - Baiyunshan - Sinopharm [4] High-end Medical Equipment - Recommended companies benefiting from overseas pharmaceutical investments include: - Sensong International - Dongfulong - Chutian Technology [4] - Companies expected to see business growth from hospital procurement recovery include: - United Imaging - Kaili Medical - Xinhua Medical - Mindray Medical - Aohua Endoscopy - Mountain Outside Mountain [4] - Companies with domestic demand-driven medical device recovery include: - Yiyue Medical - Kefu Medical - Sanofi Biotech [4] - Companies with restored overseas orders include: - Meihua Medical - Haitai New Light - Ruimaite [4] - Companies with increasing market penetration in high-end medical consumables include: - Xinmai Medical - Micron Medical - Weigao - Micron Brain Science - Aikang Medical - Chunli Medical [4]

Core Viewpoint - The stock of Xinmai Medical (688016) has shown a slight increase, with a closing price of 93.18 yuan on December 5, 2025, reflecting a 1.28% rise, while the overall market sentiment indicates a mixed flow of funds among different investor categories [1][2]. Financial Performance - For the first three quarters of 2025, Xinmai Medical reported a main business revenue of 1.015 billion yuan, a year-on-year increase of 4.66% [3]. - The net profit attributable to shareholders was 429 million yuan, representing a year-on-year decline of 22.46% [3]. - The company's gross profit margin stands at 70.4%, significantly higher than the industry average of 51.22% [3]. - The net profit margin is 41.69%, which is substantially above the industry average of 9.57% [3]. Market Position - Xinmai Medical's total market capitalization is 11.486 billion yuan, slightly above the industry average of 11.035 billion yuan [3]. - The company ranks 16th in net profit within the medical device industry, with a price-to-earnings ratio of 20.08, which is considerably lower than the industry average of 64.34 [3]. Recent Trading Activity - On December 5, 2025, the net outflow of main funds was 442.24 million yuan, accounting for 5.52% of the total transaction amount [1][2]. - Retail investors showed a net inflow of 544.67 million yuan, representing 6.80% of the total transaction amount on the same day [1][2]. Analyst Ratings - In the last 90 days, 9 institutions have rated Xinmai Medical, with 7 buy ratings and 2 hold ratings, indicating a generally positive outlook [4]. - The average target price set by analysts over the past 90 days is 136.03 yuan [4].

Group 1 - The report highlights a significant divergence in the performance of various sub-sectors within the pharmaceutical industry in 2025, with the CXO and innovative drug-related sectors showing substantial growth, while the medical service sector is expected to gradually recover in 2026 due to a low base effect from 2025 [2][6][58] - The overall performance of the A-share market was positive in 2025, with the pharmaceutical and biological sector ranking 10th with a growth of 34.95%, while the CXO sector led with a growth of 58.71% [6][15] - The report emphasizes the importance of "product-driven" companies, which are expected to enter a profitability cycle as they recover from the impacts of centralized procurement and increase their R&D investments [2][29] Group 2 - The innovative drug sector is projected to continue its upward trend, with business development (BD) opportunities abroad being a key focus, indicating the global competitiveness of Chinese innovative drugs [30][34] - The medical device sector is also expected to follow a similar recovery path as innovative drugs, with increasing R&D investments and a growing number of approved innovative medical devices [43][45] - The medical service sector, despite facing short-term pressures, is anticipated to gradually recover in 2026, supported by an aging population and increasing demand for healthcare services [58] Group 3 - The report suggests specific companies to watch in various sectors, including medical devices (e.g., Sanyou Medical, Aikang Medical), innovative drugs (e.g., Innovent Biologics, Kintor Pharmaceutical), and medical services (e.g., Aier Eye Hospital, Tongce Medical) [2][29] - The report notes that the pharmaceutical sector's overall valuation remains at a historical low, with a price-to-earnings ratio of 30.82 times as of October 31, 2025, indicating potential for upward adjustment [19][20] - The report highlights the importance of key product advancements and performance realization in the innovative drug sector, particularly for products like PD-1/VEGF, which have shown promising clinical data and significant market interest [39][40]

证券日报网讯12月1日，心脉医疗在互动平台回答投资者提问时表示，根据公司2025年第三季度报告， 截至2025年9月30日，公司股东总数为15，990户。 ...